Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics to Treat Ciliopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River & Axovia Partner to Support Development of Gene Therapies for Ciliopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Axovia Therapeutics

    Menu

    Axovia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Axovia Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Charles River & Axovia Partner to Support Development of Gene Therapies for Ciliopathies

              Details:

              The collaboration aims to support the development of Axovia’s gene therapies, including AXV101, for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.

              Lead Product(s): AXV101

              Therapeutic Area: Genetic Disease Product Name: AXV101

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: Charles River Laboratories, Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axovia Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics to Treat Ciliopathies

              Details:

              Axovia is developing the first gene therapies for ciliopathies and has a pipeline of products, including AXV101, an AAV9-based gene therapy targeting retinal dystrophy associated with BBS in patients carrying biallelic mutations in the BBS1 gene.

              Lead Product(s): AXV101

              Therapeutic Area: Genetic Disease Product Name: AXV101

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: ALSA Ventures

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition September 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY